Abstract

Introduction: Peritoneal dialysis-related peritonitis (PDRP) should be treated as soon as possible by an empirical regimen without waiting for effluent bacterial culture results. We retrospectively investigated patients treated with vancomycin plus levofloxacin as a treatment regimen if there was no response to cefazolin plus ceftazidime.
Materials and methods: We collected records of adult patients with PDRP from January 1, 2013, to November 30, 2020. The characteristics of episodes of PDRP with no response to cefazolin plus ceftazidime treated by intraperitoneal (IP) injection of vancomycin plus levofloxacin were analyzed.
Results: 118 episodes of PDRP were recorded, among which 115 episodes were treated with IP antibiotics. 93 episodes were treated with cefazolin plus ceftazidime. In 38 episodes, treatment was switched to IP injection of vancomycin plus levofloxacin if there was no response to cefazolin plus ceftazidime. 26/38 (68.4%) episodes were cured by vancomycin plus levofloxacin. Fever, diabetes, fasting glucose, a decrease in effluent leukocytes on day 3 and day 5, and Charlson Comorbidity Index (CCI) scores were significantly different between uncured and cured episodes. No variable was associated with treatment failure after multiple logistic regression. Fever, diabetes, a decrease in effluent leukocytes on day 3, and CCI score were associated with treatment failure after univariable logistic regression.
Conclusion: Vancomycin plus levofloxacin may be effective if patients are not responsive to cefazolin plus ceftazidime.

*Jiafan Zhou and Yajuan Huang contributed equally to this work.

Author Details

Authors

• Jiafan Zhou*
• Yajuan Huang*
• Xing Zhang
• Liping Xiong
• Rui Zhang
• Hongrui Shi

Departments

• Department of Nephrology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

Address

Hongrui Shi, MD
or
Rui Zhang, MD, PhD
Department of Nephrology
the Sixth Affiliated Hospital
Sun Yat-sen University
No. 26, Yuancun Erheng Road
Guangzhou, Guangdong, 510655, China
Email: [email protected]; [email protected]

Log in for Subscribers

Citation